Neonatal BNP and metabolic syndrome risk in adolescents
Exploring B-Type Natriuretic Peptide (BNP) Evolution, From the Neonatal to Adolescent Period, as a Tool to Early Identify the Risk for Metabolic Syndrome (MetS) in a Former Preterm and Full Term Adolescent Population
Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07181733
This project will see if newborn BNP levels and early heart ultrasound measurements are linked to metabolic syndrome in adolescents who had those tests as infants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 13 Years to 18 Years |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia (other) |
| Locations | 1 site (Pavia, pavia) |
| Trial ID | NCT07181733 on ClinicalTrials.gov |
What this trial studies
This is a retrospective observational analysis of adolescents born in 2009-2011 who had BNP concentrations and echocardiographic parameters measured during their first month of life. Researchers will identify which participants meet pediatric metabolic syndrome criteria (using commonly cited definitions such as Cook, Zimmet, and de Ferranti) and compare early-life BNP and echo findings between those with and without metabolic syndrome. The study uses clinical record review and statistical analysis (including factor or risk-score approaches) to look for associations between neonatal cardiac biomarkers/measurements and later metabolic risk. There are no interventions; the goal is to identify potential early-life markers of cardiometabolic risk.
Who should consider this trial
Good fit: Adolescents born in 2009-2011 who have documented BNP levels and echocardiography performed during the first month of life and available records at the Pavia pediatric cardiology unit.
Not a fit: Patients without documented neonatal BNP or echocardiographic data, or those outside the adolescent age cohort, are unlikely to benefit from this specific analysis.
Why it matters
Potential benefit: If successful, neonatal BNP or early echo findings could help identify children at higher risk for metabolic syndrome so earlier prevention or monitoring can be offered.
How similar studies have performed: While adult studies have linked natriuretic peptides to metabolic traits, longitudinal pediatric evidence is limited and this application in adolescents is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adolescents whose BNP concentration and echocardiographic parameters analysed during their first month of life (2009-11)
Where this trial is running
Pavia, pavia
- U.O.S. Cardiologia Pediatrica — Pavia, pavia, Italy (RECRUITING)
Study contacts
- Study coordinator: Alessia C.A. Codazzi, MD
- Email: a.codazzi@smatteo.pv.it
- Phone: +390382502915
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Metabolic Syndrome, adolescent, BNP